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Abstract
Objective: Only a limited proportion of patients needing pharmacological control of portal hypertension are hemodynamic
responders to propranolol. Here we analyzed the effects of zolmitriptan on portal pressure and its potential interaction with
propranolol.
Methods: Zolmitriptan, propranolol or both were tested in two rat models of portal hypertension: common bile duct
ligation (CBDL) and CCl4-induced cirrhosis. In these animals we measured different hemodynamic parameters including
portal venous pressure, arterial renal flow, portal blood flow and cardiac output. We also studied the changes in superior
mesenteric artery perfusion pressure and in arterial wall cAMP levels induced by zolmitriptan, propranolol or both.
Moreover, we determined the effect of splanchnic sympathectomy on the response of PVP to zolmitriptan.
Results: In both models of portal hypertension zolmitriptan induced a dose-dependent transient descent of portal pressure
accompanied by reduction of portal flow with only slight decrease in renal flow. In cirrhotic rats, splanchnic sympathectomy
intensified and prolonged zolmitriptan-induced portal pressure descent. Also, propranolol caused more intense and durable
portal pressure fall when combined with zolmitriptan. Mesenteric artery perfusion pressure peaked for about 1 min upon
zolmitriptan administration but showed no change with propranolol. However propranolol enhanced and prolonged the
elevation in mesenteric artery perfusion pressure induced by zolmitriptan. In vitro studies showed that propranolol
prevented the inhibitory effects of b2-agonists on zolmitriptan-induced vasoconstriction and the combination of
propranolol and zolmitriptan significantly reduced the elevation of cAMP caused by b2-agonists.
Conclusion: Zolmitriptan reduces portal hypertension and non-selective beta-blockers can improve this effect. Combination
therapy deserves consideration for patients with portal hypertension failing to respond to non-selective beta-blockers.
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Introduction
Portal hypertension is the main complication of liver cirrhosis. It
develops in the majority of patients and is responsible for massive
gastrointestinal bleeding from ruptured gastro-esophageal varices.
Portal hypertension also plays a key role in other complications of
cirrhosis, such as ascites, hepatorenal syndrome and hepatic
encephalopathy [1]. Portal hypertension is associated with the
development of hyperdynamic circulation as result of intense
splanchnic vasodilation and increased splanchnic blood flow [2].
Pharmacological therapy of this condition is basically aimed at
correcting the increased portal blood inflow using splanchnic
vasoconstrictors. Some of these drugs, such as non-selective beta-
blockers (NSBB), can be given orally and are therefore appropriate
for long-term administration. Propranolol is the drug most
commonly used in portal hypertensive patients. Propranolol seems
to act by limiting the splanchnic vasodilating effects resulting from
the enhanced b2-adrenoceptor drive present in cirrhotic patients
owing to increased sympathetic tone [3]. Others vasoconstrictors,
such as somatostatin or terlipressin, require parenteral adminis-
tration and are only used for short-term administration, as in the
treatment of acute variceal hemorrhage [1]. Unfortunately, only
37% of patients are hemodynamic responders to propranolol [4]
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and therefore new treatment regimes are much needed. Triptans
are agonists of serotonin 5-HT1B/1D/1F receptors commonly used
to treat migraine. Zolmitriptan, a selective 5-HT1B/1D receptor
agonist [5] was the first of a second generation of triptans.
Importantly, 5-HT1B/D receptors are expressed in human superior
mesenteric artery where they mediate a potent vasoconstrictor
effect [6]. The aim of our study was to evaluate whether
zolmitriptan may reduce experimental portal hypertension, to
analyze the pharmacological interaction between zolmitriptan and
propranolol and to determine if zolmitriptan can provide better
control of PVP in combination with propranolol.
Materials and Methods
Animals Care
Male Sprague-Dawley rats were purchased from Harlan
Laboratories (Italy). Rats weighing 300–350 g were used. Animals
were maintained under standard conditions in environmentally
controlled animal facilities. All procedures were approved by the
by the University of Navarra Animal Care Committee (approval
ID: 013/10 and 096/10 ). All surgery was performed under
inhalational anesthesia, and all efforts were made to minimize
suffering. Sacrifice was performed during deep anesthesia.
Induction of Portal Hypertension
a) Common bile duct ligation (CBDL). Under isoflurane
anesthesia (Abbott Laboratories, UK) the bile duct was doubly
ligated with 3–0 non absorbable silk thread (ETHICON, USA)
and then resected between the two ligatures. Ketoprofeno (Merial,
France) was administered for analgesic purposes. Vitamin k
(Roche, Spain) and enrofloxacin (Laboratorios Ovejero, Spain)
were administered after surgery to improve survival. Two or four
weeks after surgery rats were used in hemodynamic studies.
b) Liver cirrhosis was provoked by repeated oral
administration of CCl4 [7]. Rats were given phenobarbital
(Kern Pharma, Spain) in their drinking water throughout all the
period of liver cirrhosis induction. One week after, CCl4 (Sigma-
Aldrich, Spain) diluted in water was administered orally by
gavage. The initial dose was 20 ml and subsequent administrations,
on a weekly basis, were dose-adjusted based on changes in body
weight. After 12–20 weeks of CCl4 gavage, administration of CCl4
and phenobarbital was stopped and studies were performed one
week later.
Hemodynamic Determinations
All animals were fasted 12 hours before surgery. Measurements
were conducted under general inhalation anesthesia (1.5%
isoflurane). Continuous anesthetic administration was used to
reduce oscillations in drug concentration. Furthermore, isoflurane
has been shown to preserve hemodynamic parameters in cirrhotic
rats [8–9]. A homeothermic blanket (Panlab, Spain) was used to
maintain body temperature at 37uC. Portal vein was cannulated
via the ileocolic vein with a catheter (22G BD, Spain) connected to
a physiological pressure transducer (AD instruments, Australia) to
monitor portal venous pressure (PVP). A perivascular ultrasonic
transit-time flowprobe (0.7PSB for arterial renal flow (ARF), and
2PSB for portal blood flow (PBF)) (Transonic Systems, USA) was
used to measure flow (ml/min). The flow probe was connected to a
small animal flowmeter (Transonic Systems, USA). Systemic
arterial pressure (MAP) was measured from a fluid-filled catheter
placed in a carotid artery (20G). Cardiac output (CO) was
determined using ultrasound velocity dilution method as previ-
ously described [10]. Blood pressure and flow were registered on a
multichannel computer based recorder (AD instruments, Austra-
lia). Heart rate (HR) (beats/min) was obtained from arterial blood
flow recordings. Systemic vascular resistance (SVR) was calculated
as: MAP/CO. Basal measurements were obtained approximately
20 minutes after probe implantation to allow stabilization.
Femoral vein was catheterized (24G) for drug infusion.
Determination of Mesenteric Artery Perfusion Pressure
In situ perfusion of the rat mesentery is a simple and useful
method to eliminate the influence of a variety of physiologic
influences or homeostatic responses [11]. Rats were anaesthetized
with sodium pentobarbital (60 mg/kg, i.p.) (Hospira, Holland).
Tracheotomy was performed and catheters were placed in the
right and left carotid arteries. Left carotid artery was cannulated
for blood pressure measurements using a pressure transducer
(Spectramed, South Africa) and a physiograph recorder (Grass,
USA). Intact vascular beds were perfused using an extracorporeal
circuit and a constant flow Gilson peristaltic pump [12]. Heparin
(5 mg/kg) (Hospira, Spain) was then administered by a cannula
placed in the left jugular vein. The circuit was established with no
interruption of blood flow to the mesenteric bed, pumping from
the right carotid artery to the superior mesenteric artery (SMA).
The distal portion of the external circuit was connected to a
pressure transducer and physiograph recorder. At the beginning of
each experiment, flow was adjusted to render the perfusion
pressure (PP) equal to the systemic pressure. Flow was kept
constant throughout the experiment, changes in the perfusion
pressure reflecting the changes in the vascular resistances. The
flow rate through the mesenteric vascular bed ranged from 1.5 to
2 ml min21, depending on the animal systemic pressure [12–13].
After a 15 min period of stabilization, experiments were
performed using six animals to evaluate zolmitriptan (10 mg/kg),
propranolol (4.5 mg/kg) or the combination of both. In other set
of experiments (N = 5) atenolol (4.5 mg/kg), ICI-118,551 (4.5 mg/
kg) or the combination of each one with zolmitriptan were tested.
Drugs were dissolved in DMSO and administered intra-arterially
via the distal cannula by bolus injection of a maximum of 10 ml
using a microsyringe (Exmire, Japan).
Splanchnic Sympathetic Denervation
Selective chemical sympathectomy (SS) in the splanchnic and
peritoneal area was carried out as previously described [14]. A
saporin-coupled anti-dopamine-b-hydroxylase antibody (Advance
Targeting Systems, USA) was intraperitoneally injected (5 mg/ml
in 3 ml of saline) to CCl4-treated rats (N = 4). This is a highly
specific noradrenergic damaging agent as it specifically targets cells
that express dopamine beta-hydroxylase. Once the immunotoxin
has reached the nucleus of the axon, saporin is released and it
irreversibly blocks protein synthesis, inducing cell death. Saline
alone was given as a control. The efficacy of SS was assessed by
measurement of norepinephrine levels in mesenteric organs
(spleen, small intestine) with an immunoassay (LDN, Germany).
In vitro Assessment of Mesenteric Artery Contraction
Endothelium-intact mesenteric arterial rings (internal diameter
0.3–0.6 mm) were mounted in a wire myograph in Krebs solution
and stretched to an equivalent transmural pressure of 100 mmHg
[15]. After equilibration, arteries were mildly depolarized by a
threshold concentration of KCl (25 mM) which enhances the
contractile responses to zolmitriptan as previously described for
other 5HT1B agonists in human mesenteric arteries [16],
resembling the in vivo responses. In some experiments, arteries
were exposed to the b-adrenoceptor agonist isoproterenol
(0.1 nM) to mimic the in vivo endogenous b-adrenergic sympa-
thetic tone. Then, arteries were exposed to zolmitriptan (10 and
Zolmitriptan and Propranolol on Portal Pressure
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100 mM) followed by propranolol (1 mM) or to propranolol
followed by zolmitriptan (N$5).
Determination of Cyclic AMP (cAMP) in the Wall of
Mesenteric Artery
Under general inhalation anesthesia (isoflurane), healthy rats
(N$4) were injected via a femoral vein with isoproterenol (1 mg/
kg) or the same volume of saline. The induction of cAMP with this
b-adrenergic agonist allows us to quantify the inhibition of the
tested drugs. The other femoral vein was cannulated to inject
propranolol (5 mg/kg) or zolmitriptan (10 mg/kg) preceded or not
by propranolol injection. Propranolol was infused during 60
seconds and zolmitriptan infusion was stopped after 5 min, when
its maximal effect has been described. Rats were sacrificed 6
minutes after the injection and SMA was removed and snapped
frozen in liquid nitrogen. Tissues were grounded in a mortar and
pestle under liquid nitrogen and tested in accordance with the
manufacturer’s instructions (Detect XH Direct Cyclic AMP, Arbor
Assays, USA). Protein concentration was determined using the
BCA method (Sigma, USA).
Drug Administration
a) Acute experiments. In CCl4-treated or CBDL rats
hemodynamic data (PVP, ARF, and PBF) were recorded at
baseline and then continuously during and after intravenous
infusions of zolmitriptan, propranolol, nadolol and terlipressin.
Propranolol and nadolol (Sigma, Spain) were diluted in saline to
the final use concentration (5 and 10 mg/kg, respectively).
Zolmitriptan (Astra Zeneca, Spain) was diluted in saline and
administered at the indicated dose. Terlipressin (Ferring, Spain)
was prepared as indicated by the manufacturer and administered
at the indicated dose. In the experiments to determine CO and
MAP, zolmitriptan (10 mg/kg) and terlipressin (50 mg/kg) were
administered as a bolus injection. MAP was continuously recorded
while CO determinations were obtained before and after each
drug administration, at the point of maximum drug effect (10 and
20 min respectively).
b) Chronic experiments. CBDL rats were randomly allo-
cated to two groups that received zolmitriptan (10 mg/kg) or
vehicle. Zolmitriptan (Astra Zeneca) was dissolved in citric acid
and administered orally by gavage every 12 hours for 7
consecutive days. One hour after the morning dose in day 8, rats
were anesthetized, hemodynamic data were obtained and blood
samples were collected from the ileocolic vein for biochemical
testing. After sacrifice, liver samples were harvested for histo-
chemical analysis in 3.7–4% formaldehyde (Panreac, Spain).
Laboratory Tests
Blood samples for biochemistry were collected in Vacutainer
tubes (BD, UK). After one hour incubation at 37uC, tubes were
centrifuged at 2500 RPM for 15 min at RT. Serum was collected
and kept at 220uC until analysis. Biochemical parameters were
measured using a Cobas Integra Analytical system C311 (Roche,
UK).
Statistics
Data are expressed as mean 6 SEM. Statistical significance was
determined by Student’s t test or Mann-Whitney test (N,6) for
comparisons between two groups. ANOVA test with Bonferroni’s
post-test or Kruskal-Wallis test with Dunn’s post’-test (N,6) were
used for multiple comparisons. Groups were checked for normality
using Shapiro-Wilk test (p$0.01). Statistical analysis was done
using GraphPad Prism 5.0 (GraphPad Software Inc., USA).
Results
Administration of Zolmitriptan to CBDL Rats: Effects on
PVP, ARF and Systemic Hemodynamics
Zolmitriptan (at doses of 5, 10 and 20 mg/kg) or saline were
infused during 20 min to two weeks-CBDL rats. General
characteristics and hemodynamic data of the animals are listed
in Table 1. As illustrated in Figure 1, we observed a significant and
dose-dependent decrease of PVP in all rats receiving zolmitriptan.
With all doses, PVP returned to baseline 5 min after the end of the
infusion (Figure 1A). Zolmitriptan caused similar effects on PVP in
four weeks-CBDL rats (Figure S1).
We also found that zolmitriptan caused a slight and transient
decrease in ARF (Figure 1B) which was significantly less intense
than that produced by doses of terlipressin that induced similar
effects on PVP (maximal reduction of ARF 17% vs 64%, p,0.05)
(Figure 1C and D). Moreover, in rats subjected to four week-
CBDL, we found that terlipressin (50 mg/kg) provoked a
substantial increase of MAP (14% with respect baseline) together
with a significant decrease of CO and a marked elevation of SVR
while zolmitriptan caused no significant changes in CO and SVR
and only a mild elevation of MAP (1% with respect baseline)
(Figure 2A, B and C).
To see whether maintenance therapy with zolmitriptan could
reduce PVP in rats with two weeks-CBDL, animals were randomly
allocated (N = 7 per group) to receive zolmitriptan (10 mg/kg) or
vehicle for 7 days. Two rats from each group died before sacrifice
and hemodynamic measurement failed for technical reasons in
one rat. We found that animals treated with zolmitriptan
experienced a decrease in PVP of 14% compared to those
receiving vehicle (p,0.05) (Figure 2D). No relevant changes in
biochemical parameters were found in association with this
therapy (Table 2).
Portal Hypotensive Effects of Zolmitriptan in Rats with
CCl4-induced Liver Cirrhosis: Effect of Splanchnic
Sympathectomy (SS)
To analyze if the effect of zolmitriptan on portal hypertension
was model-dependent we also evaluated the effect of this drug in
rats with CCl4-induced liver cirrhosis. Animals were divided into
two groups which received an intravenous infusion (20 min) of
saline or zolmitriptan (10 mg/kg). General characteristics and
hemodynamic data of the experimental groups are listed in
Table 1. As shown in Figure 3A, zolmitriptan caused a significant
reduction in PVP as compared to rats receiving saline. As in the
CBDL model, the decrease of PVP was rapid (maximum descent
at 5 min) but reverted to basal values when the infusion was
discontinued. The reduction of PVP was accompanied by a slight
but statistically significant decrease in ARF (Figure 3B) from
761.4 ml/min at baseline to 5.961.2 ml/min at the end of the
infusion (p,0.05). HR did not differ significantly between the two
groups (319620 bpm vs 322620 bpm). MAP remains quite stable
in this model of portal hypertension, even at high doses (20 mg/
kg), with only a slight transient decrease of its values at the
initiation of the infusion (Figure S2). Also, we observed that
zolmitriptan caused a diminution of PBF (Figure 3C) which
paralleled the descent in PVP suggesting that this drug reduces
portal blood inflow by promoting mesenteric artery vasoconstric-
tion.
As noted above, the fall in PVP that occurs in cirrhotic rats
treated with zolmitriptan reverts soon after discontinuing drug
infusion. To determine whether sympathetic innervation might
counteract the splanchnic vasoconstrictive activity of zolmitriptan
we infused this drug in two groups of rats with CCl4-induced liver
Zolmitriptan and Propranolol on Portal Pressure
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cirrhosis, of which one was subjected to SS, while the other group
received saline instead (Figure S3). We found that in the control
group PVP was reduced during zolmitriptan infusion but reverted
to baseline upon cessation of drug infusion while in the group
subjected to SS the descent of PVP persisted during all the study
period (Figure 3D).
NSBBs Prolong and Enhance the Portal Hypotensive
Effect of Zolmitriptan in Rats with CCl4-induced Liver
Cirrhosis
Propranolol, a NSBB which is the cornerstone therapy for the
prevention of variceal bleeding, lowers PVP by blocking b1- and
b2-receptors. The effect of b1-blockade, which reduces CO,
Figure 1. Effect of intravenous infusion of zolmitriptan and terlipressin in CBDL-rats. (A,C) Portal pressure (PVP). (B,D) Renal flow (ARF).
*p,0.05 vs saline. */**p,0.05/0.01 vs zolmitriptan dose 10 mg/kg.
doi:10.1371/journal.pone.0052683.g001
Table 1. Body weight, biochemical data and basal hemodynamic parameters of rats with portal hypertension which received i.v.
infusion of zolmitriptan, terlipressin or saline.
CCl4 model CBDL model
Saline (N=4) Zolmitriptan (N=6) Saline (N=4) Zolmitriptan (N=14) Terlipressin (N=7)
Body weight (g) 402 (360–489) 443 (393–483) 383 (331–416) 381 (275–408) 407 (307–438)
ALP (U/L) 115 (80–244) 163 (115–289) 653 (561–677) 476 (318–753) 433 (82–1399)
ALT (U/L) 44 (21–52) 56 (44–108) 255 (200–356) 209 (104–460) 145 (8–329)
bilirubin (mg/dL) 0.2 (0.1–0.6) 0.2 (0.1–0.4) 15.4 (12.3–18.4) 11.5 (9–17) 10.1 (0.2–15)
albumin (g/dL) 3.2 (3–3.4) 3 (2.6–3.2) 4 (3.1–4.1) 2.9 (2.5–4.1) 3 (0.6–4)
Hemodynamic data
PVP (mm Hg) 11.660.9 12.760.5 13.160.6 14.160.5 13.860.7
Renal flow (ml/min) 6.461.3 7.060.6 5.460.6 4.260.6 4.260.4
heart rate (beats/min) 325612.3 332617.4 330610.5 335610.81 332620
Values of body weight and biochemical variables are expressed as median and ranges and hemodynamic data are expressed as mean6SEM. ALP: alkaline phosphatase,
ALT: alanine transaminase, AST: aspartate aminotransferase, PVP: portal vein pressure.
doi:10.1371/journal.pone.0052683.t001
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appears to be less relevant than the effect of b2-blockade which
promotes splanchnic vasoconstriction by preventing vasodilation
[17]. Since zolmitriptan induces splanchnic vasoconstriction, it is
reasonable to hypothesize that this drug may cooperate with
propranolol in lowering PVP. To analyze the interaction of
zolmitriptan and NSBB, we infused zolmitriptan (10 mg/kg
during 20 min) after a 10-min infusion of propranolol or nadolol
to rats with CCl4-induced liver cirrhosis (general features and
hemodynamic data of the animals are presented in Table S1). We
used the model of CCl4-induced liver cirrhosis since it was
reported that propranolol has no hemodynamic effects in CBLD
rats [18]. As expected, propranolol and nadolol produced a
significant reduction in HR (215% and 28% respectively,
p,0.01) and PVP (26%, p,0.05 and27%, p,0.01, respectively)
when compared to saline (Figure 4 A and C). The combination of
propranolol or nadolol with zolmitriptan resulted in a significant
decrease in PVP (216%, p,0.01) compared to rats receiving
NSBB alone. Interestingly, the reduction of PVP achieved by
combining NSBB and zolmitriptan was more durable and
persisted beyond drug infusion. This is in contrast with the
transient fall in PVP observed when zolmitriptan was administered
alone (see Figure 3). Of note, the drop in HR did not differ
significantly between groups receiving NSBB or the combination
therapy (Figure 4B and D).
Effect of Zolmitriptan Alone or in Combination with NSBB
on Superior Mesenteric Artery Perfusion Pressure (SMA-
PP)
To further analyze the interaction between propranolol and
zolmitriptan on mesenteric artery vasoconstriction, we evaluated
the SMA-PP in healthy rats treated with the drugs. In previous
Figure 2. Systemic and chronic effects of zolmitriptan and terlipressin in CBDL-rats. Measurement of arterial pressure (MAP) (A), cardiac
output (CO) (B) and systemic vascular resistance (SVR) (C) after zolmitriptan, terlipressin or saline administration. (D) Effect of chronic administration of
zolmitriptan in portal pressure (PVP). */**p,0.05/0.01 vs saline.
doi:10.1371/journal.pone.0052683.g002
Table 2. Biochemical data and hemodynamic parameters in
CBDL rats after chronic treatment with zolmitriptan or vehicle.
CBDL model
vehicle (N=5)
zolmitriptan
(N=5)
alkaline phosphatase (U/L) 415.4612.0 481.86133
alanine transaminase (U/L) 92.663.2 91.6618.9
aspartate aminotransferase (U/L) 398.4611.8 4106118.1
bilirubin (mg/dL) 12.160.3 10.360.6
albumin (g/dL) 3.160.1 2.660.1 a
Hemodynamic data
portal pressure (mm Hg) 16.260.8 13.960.2 a
Data are expressed as mean6SEM. a compared to the vehicle group, p,0.05.
doi:10.1371/journal.pone.0052683.t002
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experiments we observed that the decrease in SMA blood flow was
similar in cirrhotic and healthy rats indicating that liver cirrhosis
does not decrease the sensitivity of the splanchnic vasculature to
the vasoconstrictive effects of zolmitriptan. After intra-arterial
administration of zolmitriptan (10 mg/kg), propranolol or the
combination of both, we observed that unlike propranolol or
vehicle, zolmitriptan induced a marked but short lasting (about 1
minute) increase in SMA-PP. Interestingly, when zolmitriptan was
given in combination with propranolol, the increase in PP was
similar but lasted longer (nearly 30 min) (Figure 5A). In order to
discern the role of each beta-adrenergic receptor in this
vasoconstrictor effect, we measured SMA-PP after injection of
specific b1- (atenolol) and b2-(ICI-118,551) blockers and after the
combined administration of each one of them with zolmitriptan
(Figure 5B). None of the beta-blockers modified PP when injected
alone. Interestingly, while atenolol did not change the contractile
response to the triptan, the joint administration of zolmitriptan
with the b2-blocker resulted in a prolonged increase in PP
comparable to that seen after administration of zolmitriptan plus
propranolol.
Effect of Zolmitriptan in Combination with NSBB on
Catecholamine-induced Relaxation of Mesenteric Artery
in vitro
In preliminary experiments, we observed that zolmitriptan
produced a weak and variable contractile response in isolated
mesenteric arteries but when arteries were exposed to 25 mM
KCl, the triptan induced a dose-dependent contractile response
(Figure 5C, upper graph). Propranolol had no apparent effect on
vascular tone, due to the absence of sympathetic tone in these
in vitro experiments. The b-adrenoceptor agonist isoproterenol
strongly relaxed KCl-induced contraction and inhibited the
contraction promoted by zolmitriptan, a response which was
restored by subsequent addition of propanolol to the incubation
medium (Figure 5C, middle graph). In another set of experiments,
pre-incubation of the SMA with propranolol reversed the
relaxation induced by isoproterenol and facilitated the contractile
response to zolmitriptan (Figure 5C, lower graph). Altogether,
these experiments indicate that b2-receptor activation attenuates
zolmitriptan-induced SMA vasoconstriction and that this inhibi-
tory effect is reversed by propranolol.
Effect of Zolmitriptan in Combination with NSBB on
cAMP Levels in the Wall of Mesenteric Artery
b2-receptor activation increases intracellular cAMP levels which
mediate relaxation of smooth muscle cells of the arterial wall [19].
Thus, we decided to analyze the effect of zolmitriptan, propranolol
and the combination of the two drugs on cAMP levels in the
mesenteric artery wall. To this aim rats received a bolus of
isoproterenol, followed by an intravenous injection of propranolol
or an infusion of zolmitriptan preceded or not by propranolol
injection. A group receiving saline served as control. Animals were
sacrificed 6 minutes after treatment and mesenteric artery was
sampled for cAMP determinations. Isoproterenol promoted a
Figure 3. Effect of intravenous infusion of zolmitriptan in CCl4-treated rats. (A) Portal pressure (PVP). (B) Renal flow (ARF). (C) Portal flow
(PBF). (D) Portal pressure after SS. */** significance vs saline or sham p,0.05/0.01.
doi:10.1371/journal.pone.0052683.g003
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significant increase (p,0.05) of cAMP levels in the arterial wall
and both zolmitriptan and propranolol tended to attenuate this
effect but the differences with isoproterenol alone were not
statistically significant. However the combination of the two drugs
showed an additive effect that caused a more intense and
statistically significant (p,0.05) reduction of cAMP in the SMA
wall compared to isoproterenol alone (Figure 5D).
Discussion
Zolmitriptan is a selective serotonin 5-HT1B/1D receptor agonist
with proven benefit in the treatment of migraine as result of its
cranial vasoconstrictive effect. [20]. Several clinical trials have
confirmed the efficacy and favorable safety profile of this drug
[21]. In addition to acting on cranial vessels, zolmitriptan also
causes peripheral vasoconstriction in specific territories. Of
particular interest when considering possible therapies for portal
hypertension is the fact that 5HT1B/D receptors abound in human
SMA where they mediate robust vasoconstrictive effects [6] [22].
Therefore we have tested zolmitriptan as a therapeutic option for
subjects with portal hypertension, since drugs able to reduce blood
inflow into the splanchnic area could be potentially useful to
reduce the risk of bleeding from esophageal varices in these
patients and to treat variceal hemorrhage.
In the present study we show that zolmitriptan causes a dose-
dependent reduction of PVP in rats with portal hypertension. This
effect is associated with a parallel reduction of PBF accompanied
by increased mesenteric vascular resistance, indicating that
vasoconstriction of splanchnic arteries is a key mechanism
implicated in the reduction of PVP. Zolmitriptan has several
advantages in the treatment of patients with portal hypertension
including its modest influence on MAP and ARF (even at high
doses) which is not comparable to the effects of terlipressin. Our
results with zolmitriptan in experimental animals are in accor-
dance with pharmacological studies in humans where no
significant changes in MAP have been described [23]. Also,
previous studies indicate that sustained zolmitriptan administra-
tion does not cause tachyphylaxis [24–25]. In agreement with
these data we observed 14% reduction of PVP in CBDL rats
treated with zolmitriptan for one week. Moreover there are reports
of its good tolerability after repeated administration in patients
[26] [23].
The portal hypotensive effect of zolmitriptan is transient as PVP
returns to basal values rapidly upon interruption of drug infusion.
Our study indicates that adrenergic drive opposes the splanchnic
vasoconstrictive effect of zolmitriptan. By performing SS we
showed that elimination of sympathetic impulse augmented and
prolonged the reduction in PVP induced by zolmitriptan.
Moreover our in vitro experiments demonstrated that SMA-
contraction induced by zolmitriptan was abrogated by isoproter-
enol and restored by addition of propranolol. Accordingly, we
found that combining zolmitriptan and propranolol reduced PVP
to a greater extent and also for a longer period of time.
Prolongation of the vasoconstrictive effect of zolmitriptan by
concurrent administration of NSBB was also observed by
measuring PP following injection of zolmitriptan, propranolol or
both into the SMA. In these studies propranolol had no effect on
the PP while zolmitriptan caused an abrupt but brief elevation of
this parameter. Importantly, the injection of both drugs resulted in
a marked prolongation of zolmitriptan vasoconstrictive effect.
Interestingly, this additive effect was achieved even at a low dose of
propranolol. Low dose of NSBB causes unopposed splanchnic
vasoconstriction, leading to reduced PBF and, consequently,
decreased portal hypertension. As the dose is increased, PBF is
further reduced by the negative effect of NSBB on CO [27].
It has been reported that propranolol inhibits the metabolism of
zolmitriptan [28]. Thus, we tested if other beta-blocker devoid of
metabolic interference, such as nadolol [29], used in combination
Figure 4. Effect of zolmitriptan in combination NSBB in CCl4-treated rats. Propranolol or nadolol were administered as an intravenous
infusion and 5 minutes later, zolmitriptan or saline infusion were started and portal pressure (PVP) (A,C) and heart rate (HR) (B,D) recorded. Infusion
time is indicated with black (beta-blockers) and grey bars (zolmitriptan). */* indicates significance vs rats receiving only NSBB (p,0.05/0.01).
doi:10.1371/journal.pone.0052683.g004
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with zolmitriptan acted similarly on PVP. Our data showed that
the decrease in PVP was similar when zolmitriptan was combined
with propranolol or with nadolol. These results suggest that the
enhancement of the portal hypotensive effects observed when
triptans and NSBB are given in combination are due to
pharmacological interaction of the two drugs rather than changes
in drug metabolism. To further explore the mechanism of this
interaction we used selective b1- and b2-blockers in combination
with zolmitriptan. We found that b2-adrenoceptor blocking
activity was responsible for propranolol synergy with zolmitriptan.
Unlike b1-receptors almost exclusively present in the heart, b2-
receptors are located in blood vessels. These receptors are
abundant in the splanchnic vasculature where they cause
vasodilatation mediated by cAMP [19]. It is well documented
that cirrhosis is associated with high levels of circulating
catecholamines and elevated cAMP production in the splanchnic
circulation [30]. These changes contribute to increase portal vein
inflow and PVP. In the present study we found that activation of
5HT1B/D receptors with zolmitriptan and inhibition of beta-
adrenergic receptors with propranolol cooperate in reducing
cAMP in the wall of SMA and therefore in attenuating the
decrease in splanchnic vascular resistances present in liver
cirrhosis. This is consistent with the canonical signaling pathways
of these two G-coupled receptors which involve the inhibition and
activation, respectively, of cAMP synthesis by adenylyl cyclase [19]
[31].
Propranolol is the cornerstone of pharmacological treatment of
portal hypertension but only 37% of patients are hemodynamic
responders [4]. Our findings suggest a potential use of zolmitriptan
in combination with b-blockers in the pharmacological treatment
of portal hypertension particularly for patients who are refractory
to beta-blockers. Interestingly, patients with frequent migraine
attacks receiving triptans have been treated with beta-blockers in
order to obtain better control of migraine [29]. A similar paradigm
could be proposed for portal hypertension.
In conclusion, our data give support for future clinical trials
directed to test the effect of combination therapy of NSBB and
triptans in the prevention of variceal bleeding in cirrhotic patients
with portal hypertension.
Supporting Information
Figure S1 Effect of zolmitriptan in PVP (A) and ARF (B) in
4 week-CBDL rats (N=4 per group). Zolmitriptan (10 mg/kg)
was administered through the femoral vein catheter as an infusion
(20 min). Values are presented as mean6SEM. *p,0.05 vs saline.
PVP: portal venous pressure, ARF: arterial renal flow.
(PDF)
Figure 5. Effects of zolmitriptan in combination with beta-blockers on splanchnic vasculature of healthy rats. (A,B) Zolmitriptan alone
or in combination with propranolol, atenolol and ICI-118,551 were administered intra-arterially and perfusion pressure recorded. (C) In vitro
mesenteric artery contraction studies after zolmitriptan and propranolol administration in the presence or absence of isoproterenol. (D) cAMP
measurement in mesenteric artery wall after administration of zolmitriptan, propranolol or the combination or both in the presence of isoproterenol.
*/*p,0.05 vs control group/group receiving only isoproterenol.
doi:10.1371/journal.pone.0052683.g005
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Figure S2 Effect of zolmitriptan in PVP (A), ARF (B), HF
(C) and MAP (D) in CCl4-treated rats (N=5 per group).
Zolmitriptan (20 mg/kg) was administered through the femoral
vein catheter as an infusion (20 min). Values are presented as
mean6SEM. */**p,0.05/0.01 vs saline. PVP: portal venous
pressure, ARF: arterial renal flow, HF: heart frequency, MAP:
mean arterial pressure.
(PDF)
Figure S3 Levels of norepinephrine in the spleen (A) and
duodenum (B) of CCl4-treated rats subjected to either
sham or splanchnic sympathectomy (SS). *p,0.05 vs
sham.
(PDF)
Table S1 Body weight, biochemical data and basal
hemodynamic parameters of rats with portal hyperten-
sion which received i.v. infusion of beta-blockers or
saline alone or beta-blockers followed by zolmitriptan.
Body weight and biochemical parameters are expressed as median
and ranges. Hemodynamic data are expressed as mean6SD.
prop: propranolol, zolm: zolmitriptan, ALP: alkaline phosphatase,
ALT: alanine transaminase, AST: aspartate aminotransferase,
PVP: portal vein pressure, ARF: arterial renal flow.
(PDF)
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